Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05137119 · ClinicalTrials.gov registry record · Phase 4
Staphylococcus Aureus Network Adaptive Platform Trial
A Phase 4 study of Staphylococcus Aureus Bacteremia, sponsored by University of Melbourne.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 8,000
- Enrollment target
- 20
- Study locations
NCT05137119: Recruiting Phase 4 study of Staphylococcus Aureus Bacteremia, sponsored by University of Melbourne.
NCT05137119 is a Phase 4 study of Staphylococcus Aureus Bacteremia that is actively recruiting participants, run by University of Melbourne. The registered enrollment target is 8,000 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (1444% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05137119, a Phase 4 study of Staphylococcus Aureus Bacteremia, is actively recruiting participants, sponsored by University of Melbourne.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 8,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
Primary Outcome
The primary endpoint for all cells and domains will be all-cause mortality at 90 days after platform entry. The primary endpoint will be determined through a search of hospital databases for a record of a participant's death, or follow-up contact with the participant's community healthcare provider, or follow-up contact with the patient or their nominated carer, or linkage with death registries.
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG Cefazolin
- DRUG Penicillin
- DRUG Clindamycin
- OTHER Effectiveness of early switch to oral antibiotics
Study Locations (20)
New South Wales
- Blacktown Hospital - Blacktown
- Royal Prince Alfred Hospital - Camperdown
- Concord Repatriation and General Hospital - Concord
- St Vincent's Hospital Sydney - Darlinghurst
- Nepean Hospital - Kingswood
- St George Hospital - Kogarah
- Liverpool Hospital - Liverpool
- John Hunter Hospital - New Lambton Heights
- John Hunter Children's Hospital - Newcastle
- Orange Health Service - Orange
- Prince of Wales Hospital - Randwick
- Sydney Children's Hospital - Randwick
- The Children's Hospital at Westmead - Westmead
- Westmead Hospital - Westmead
- Wollongong Hospital - Wollongong
Queensland
- Sunshine Coast University Hospital - Birtinya
- Cairns Hospital - Cairns
Texas
- Houston Methodist Research Institute - Houston
Australia Capital Territory
- Canberra Hospital - Garran
Northern Territory
- Royal Darwin Hospital - Tiwi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,000 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 4 |
What NCT05137119 shows while recruiting
NCT05137119 is an interventional study that assigns participants to a tested intervention. Its 8,000 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (1444% higher).
The record links to 1 condition, with Staphylococcus Aureus Bacteremia appearing as the primary indexed condition, and to 5 interventions - of which Vancomycin is the first listed.
NCT05137119 names 20 study sites across 5 states, led by New South Wales, Queensland, Texas.
Frequently Asked Questions
What is clinical trial NCT05137119 about?
NCT05137119 is a clinical study titled "Staphylococcus Aureus Network Adaptive Platform Trial". The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
What is the current status of trial NCT05137119?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 8,000 participants. The study started on 2022-02-16. Estimated completion is 2028-12-01.
What conditions does trial NCT05137119 study?
This clinical trial studies the following conditions: Staphylococcus Aureus Bacteremia.
What interventions are being tested in trial NCT05137119?
The interventions under investigation include: Vancomycin (DRUG), Cefazolin (DRUG), Penicillin (DRUG), Clindamycin (DRUG), Effectiveness of early switch to oral antibiotics (OTHER).
Who is sponsoring clinical trial NCT05137119?
This trial is sponsored by University of Melbourne, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05137119 being conducted?
This trial has 20 study locations across Texas, Australia Capital Territory, New South Wales, Northern Territory, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05137119's enrollment target sits among peer trials
8,000 10th of 2000 higher than 1,991 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00539162 · 8,000 participants · NA
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
- NCT00898638 · 8,000 participants
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
- NCT02240862 · 8,000 participants
The CREST-2 Registry
- NCT03072927 · 8,000 participants
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI